Latest & greatest articles for amiodarone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on amiodarone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on amiodarone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for amiodarone

1. Thyroidectomy for Amiodarone-Induced Thyrotoxicosis: Mayo Clinic Experience (PubMed)

Thyroidectomy for Amiodarone-Induced Thyrotoxicosis: Mayo Clinic Experience Amiodarone-induced thyrotoxicosis (AIT) is a difficult diagnostic and management challenge, especially during severe thyrotoxicosis accompanied by cardiovascular compromise.To evaluate thyroidectomy for the management of AIT.Retrospective cohort study of adults with noncongenital heart disease with AIT after >3 months of amiodarone who underwent thyroidectomy from 1 November 2002 to 31 December 2016.Referral center.The

Full Text available with Trip Pro

2018 Journal of the Endocrine Society

2. Amiodarone

Amiodarone Top results for amiodarone - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for amiodarone The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you

2018 Trip Latest and Greatest

3. Amiodarone: Wonder Drug or Wonder Why?

Amiodarone: Wonder Drug or Wonder Why? Emergency Medicine > Journal Club > Archive > January 2018 Toggle navigation January 2018 Amiodarone: Wonder Drug or Wonder Why? Vignette Working in TCC can be draining, and on one particularly busy afternoon, you begin to suspect your own sanity. After back-to-back cardiac arrest patients, you wonder if perhaps you should have done something less stressful with your life, like maybe become a lobster boat captain or an ice road trucker. Your first code (...) is a middle-aged female who suffered cardiac arrest while watching Alabama beat Clemson during the Sugar Bowl (yeah...that's right!!!). She was initially noted to be in ventricular fibrillation (VF), and remained so after three rounds of defibrillation. As she arrives in the trauma room, you immediately continue CPR and set up to shock her again. Your attending orders amiodarone, and even though you remember hearing that this may not be very effective, you realize it's not the time to argue. The patient

2018 Washington University Emergency Medicine Journal Club

4. Amiodarone, lidocaine, magnesium or placebo in shock refractory ventricular arrhythmia: A Bayesian network meta-analysis. (PubMed)

Amiodarone, lidocaine, magnesium or placebo in shock refractory ventricular arrhythmia: A Bayesian network meta-analysis. Recent evidence challenges, the superiority of amiodarone, compared to other anti-arrhythmic medications, as the agent of choice in pulseless ventricular tachycardia (VT) or ventricular fibrillation (VF). We conducted Bayesian network and traditional meta-analyses to investigate the relative efficacies of amiodarone, lidocaine, magnesium (MgSO4) and placebo as treatments (...) ranking curve (SUCRA). Bayesian analysis demonstrated that lidocaine had superior effects on survival to hospital discharge, compared to amiodarone (OR, 2.18, 95% Cr.I 1.26-3.13), MgSO4 (OR, 2.03, 95% Cr.I 0.74-4.82) and placebo (OR, 2.42, 95% Cr.I 1.39-3.54). There were no statistical differences among treatment groups regarding survival to hospital admission/24 h (hrs) and return of spontaneous circulation (ROSC). Probability analysis revealed that lidocaine was the most effective therapy

2017 Heart & lung : the journal of critical care

5. In Patients With Cardiac Arrest, Does Amiodarone or Lidocaine Increase Meaningful Survival?

In Patients With Cardiac Arrest, Does Amiodarone or Lidocaine Increase Meaningful Survival? TAKE-HOME MESSAGE Among out-of-hospital cardiac arrest patients with shock-refractory ventricular tachycardia or ventricular ?brillation, neither amiodarone nor lidocaine increases survival to hospital discharge or good neurologic outcome. In Patients With Cardiac Arrest, Does Amiodarone or Lidocaine Increase Meaningful Survival? EBEM Commentators Benton R. Hunter, MD Paul I. Musey, MD Department (...) of Emergency Medicine Indiana University School of Medicine Indianapolis, IN Results Threerandomizedcontrolledtrials (n¼3,677) and 4 observational studies (n¼704) were included for meta-analysis out of 528 articles identi?edontheinitialsearch.The results were driven by a single large (n¼3,026) randomized controlled trial at low risk of bias. The 2 smaller randomized con- trolled trials had moderate risk of bias, and the observational studies were generally at low risk of bias. Both lidocaine and amiodarone

2017 Annals of Emergency Medicine Systematic Review Snapshots

6. Amiodarone: A potential risk factor for retinal phototoxicity (PubMed)

Amiodarone: A potential risk factor for retinal phototoxicity To report the only known case, to our knowledge, of amiodarone induced retinal phototoxicity following vitrectomy surgery.A 66-year-old male presented with visual acuity of 20/150 OS secondary to an epiretinal membrane (ERM). Patient was on oral amiodarone for atrial fibrillation. Baseline spectral domain optical coherence tomography (SD-OCT) revealed an ERM with retinal thickening and schisis. The patient underwent an uncomplicated (...) showed resolution of macular edema, retinal pigment epithelium hyperplasia and an indistinct ellipsoid layer. Fluorescein angiography did not show any neovascularization. At three month follow-up, patient's vision, exam and OCT findings remained unchanged.Many pharmacologic agents have the ability to alter a patient's sensitivity to solar or artificial radiation. Drugs act as photosensitizers that lead to photochemical damage. Amiodarone has been reported to have such photosensitizing properties

Full Text available with Trip Pro

2016 American journal of ophthalmology case reports

7. Randomized comparison of intravenous procainamide vs. intravenous amiodarone for the acute treatment of tolerated wide QRS tachycardia: the PROCAMIO study (PubMed)

Randomized comparison of intravenous procainamide vs. intravenous amiodarone for the acute treatment of tolerated wide QRS tachycardia: the PROCAMIO study Intravenous procainamide and amiodarone are drugs of choice for well-tolerated ventricular tachycardia. However, the choice between them, even according to Guidelines, is unclear. We performed a multicentre randomized open-labelled study to determine the safety and efficacy of intravenous procainamide and amiodarone for the acute treatment (...) of tolerated wide QRS complex (probably ventricular) tachycardia.Patients were randomly assigned to receive intravenous procainamide (10 mg/kg/20 min) or amiodarone (5 mg/kg/20 min). The primary endpoint was the incidence of major predefined cardiac adverse events within 40 min after infusion initiation. Of 74 patients included, 62 could be analysed. The primary endpoint occurred in 3 of 33 (9%) procainamide and 12 of 29 (41%) amiodarone patients (odd ratio, OR = 0.1; 95% confidence interval, CI 0.03-0.6

Full Text available with Trip Pro

2016 EvidenceUpdates Controlled trial quality: predicted high

8. EMA recommends avoidance of certain hepatitis C medicines and amiodarone together

EMA recommends avoidance of certain hepatitis C medicines and amiodarone together EMA recommends avoidance of certain hepatitis C medicines and amiodarone together | European Medicines Agency Search Search Menu EMA recommends avoidance of certain hepatitis C medicines and amiodarone together Press release 24/04/2015 Concomitant use may increase risk of slow heart rate and related problems The European Medicines Agency (EMA) has confirmed a risk of severe bradycardia (slow heart rate) or heart (...) block (problems with conduction of electrical signals in the heart) when the hepatitis C medicines Harvoni (sofosbuvir with ledipasvir) or a combination of Sovaldi (sofosbuvir) and Daklinza (daclatasvir) are used in patients who are also taking the medicine amiodarone, which is an antiarrhythmic (a medicine used to treat irregular heartbeat). To manage this risk the Agency recommends that amiodarone should only be used in patients taking these hepatitis C medicines if other antiarrhythmics cannot

2016 European Medicines Agency - EPARs

9. Amiodarone versus Lidocaine for Arrhythmias: Comparative Clinical Effectiveness

Amiodarone versus Lidocaine for Arrhythmias: Comparative Clinical Effectiveness Amiodarone versus Lidocaine for Arrhythmias: Comparative Clinical Effectiveness | CADTH.ca Find the information you need Amiodarone versus Lidocaine for Arrhythmias: Comparative Clinical Effectiveness Amiodarone versus Lidocaine for Arrhythmias: Comparative Clinical Effectiveness Published on: January 8, 2016 Project Number: RB0949-000 Product Line: Research Type: Drug Report Type: Summary of Abstracts Result type (...) : Report Question What is the comparative clinical effectiveness of intravenous amiodarone versus intravenous lidocaine for patients in cardiac arrest or with life-threatening arrhythmias? Key Message One systematic review, two randomized controlled trials, and one non-randomized study were identified regarding intravenous amiodarone versus intravenous lidocaine for arrhythmias. Tags amiodarone, death, heart arrest, lidocaine, heart attack, Arrhythmias, Cardiac, Cardiac, Sudden Files Rapid Response

2016 Canadian Agency for Drugs and Technologies in Health - Rapid Review

10. Amiodarone method of administration for treatment of post-operative atrial fibrillation

Amiodarone method of administration for treatment of post-operative atrial fibrillation Amiodarone method of administration for treatment of post-operative atrial fibrillation Amiodarone method of administration for treatment of post-operative atrial fibrillation Mitchell MD, Strauss R, Mull N. Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database (...) . Citation Mitchell MD, Strauss R, Mull N.. Amiodarone method of administration for treatment of post-operative atrial fibrillation. Philadelphia: Center for Evidence-based Practice (CEP). 2016 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Postoperative Period Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence

2016 Health Technology Assessment (HTA) Database.

11. Amiodarone for prevention of atrial fibrillation in cardiac surgery patients

Amiodarone for prevention of atrial fibrillation in cardiac surgery patients Amiodarone for prevention of atrial fibrillation in cardiac surgery patients Amiodarone for prevention of atrial fibrillation in cardiac surgery patients Mitchell MD, Reynolds CR, Mull N Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Mitchell MD, Reynolds CR (...) , Mull N. Amiodarone for prevention of atrial fibrillation in cardiac surgery patients. Philadelphia: Center for Evidence-based Practice (CEP). 2016 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Amiodarone; Atrial Fibrillation; Cardiac Surgical Procedures; Humans Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence Center for Evidence-based Practice, University

2016 Health Technology Assessment (HTA) Database.

12. Amiodarone versus other pharmacological interventions for prevention of sudden cardiac death. (PubMed)

Amiodarone versus other pharmacological interventions for prevention of sudden cardiac death. Sudden cardiac death (SCD) is one of the main causes of cardiac death. There are two main strategies to prevent it: managing cardiovascular risk factors and reducing the risk of ventricular arrhythmias. Implantable cardiac defibrillators (ICDs) constitute the standard therapy for both primary and secondary prevention; however, they are not widely available in settings with limited resources (...) . The antiarrhythmic amiodarone has been proposed as an alternative to ICD.To evaluate the effectiveness of amiodarone for primary or secondary prevention in SCD compared with placebo or no intervention or any other antiarrhythmic drugs in participants at high risk (primary prevention) or who have recovered from a cardiac arrest or a syncope due to Ventricular Tachycardia/Ventricular Fibrillation, or VT/VF (secondary prevention).We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE

2015 Cochrane

13. Simeprevir with sofosbuvir: risk of severe bradycardia and heart block when taken with amiodarone

Simeprevir with sofosbuvir: risk of severe bradycardia and heart block when taken with amiodarone Simeprevir with sofosbuvir: risk of severe bradycardia and heart block when taken with amiodarone - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Simeprevir with sofosbuvir: risk of severe bradycardia and heart block when taken with amiodarone Avoid concomitant use of amiodarone with simeprevir (Olysio▼) and sofosbuvir (Sovaldi▼) combination therapy, unless other antiarrhythmics (...) cannot be given. Published 19 August 2015 From: Therapeutic area: , When treating patients with both heart rhythm disorders and hepatitis C: closely monitor patients taking amiodarone if they start taking the combination simeprevir and sofosbuvir; sofosbuvir and daclatasvir; and the fixed-dose combination of sofosbuvir and ledipasvir (particularly during the first weeks of treatment) only start amiodarone in patients taking any of these antiviral combinations when other antiarrhythmics

2015 MHRA Drug Safety Update

14. Sofosbuvir with daclatasvir; sofosbuvir and ledipasvir: risks of severe bradycardia and heart block when taken with amiodarone

Sofosbuvir with daclatasvir; sofosbuvir and ledipasvir: risks of severe bradycardia and heart block when taken with amiodarone Sofosbuvir with daclatasvir; sofosbuvir and ledipasvir: risks of severe bradycardia and heart block when taken with amiodarone - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Sofosbuvir with daclatasvir; sofosbuvir and ledipasvir: risks of severe bradycardia and heart block when taken with amiodarone Avoid concomitant use of amiodarone with ledipasvir (...) -sofosbuvir (Harvoni▼), and amiodarone with sofosbuvir (Sovaldi▼) and daclatasvir (Daklinza▼), unless other antiarrhythmics cannot be given. Published 20 May 2015 From: Therapeutic area: , When treating patients with both heart rhythm disorders and hepatitis C: closely monitor patients taking amiodarone if they start taking the fixed-dose combination of sofosbuvir and ledipasvir, or sofosbuvir in combination with daclatasvir (particularly during the first weeks of treatment) only start amiodarone

2015 MHRA Drug Safety Update

15. Meta-analysis of amiodarone versus beta-blocker as a prophylactic therapy against atrial fibrillation following cardiac surgery

Meta-analysis of amiodarone versus beta-blocker as a prophylactic therapy against atrial fibrillation following cardiac surgery Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2013 DARE.

16. Amiodarone versus lidocaine and placebo for the prevention of ventricular fibrillation after aortic crossclamping: A randomized, double-blind, placebo-controlled trial (PubMed)

Amiodarone versus lidocaine and placebo for the prevention of ventricular fibrillation after aortic crossclamping: A randomized, double-blind, placebo-controlled trial Ventricular fibrillation occurs commonly after aortic crossclamping in patients undergoing cardiac surgery. Ventricular fibrillation increases myocardial oxygen consumption, and defibrillation may harm the myocardium. Thus, a pharmacologic approach to decreasing the incidence of ventricular fibrillation or the number of shocks (...) required may be beneficial. The goal of this study was to evaluate whether amiodarone or lidocaine was superior to placebo for the prevention of ventricular fibrillation after aortic crossclamping in patients undergoing a variety of cardiac surgical procedures.Patients undergoing cardiac surgery requiring aortic crossclamping were randomized to receive lidocaine 1.5 mg/kg, amiodarone 300 mg, or placebo before aortic crossclamp removal The primary outcomes were the incidence of ventricular fibrillation

Full Text available with Trip Pro

2012 EvidenceUpdates Controlled trial quality: predicted high

17. Effectiveness of amiodarone versus bepridil in achieving conversion to sinus rhythm in patients with persistent atrial fibrillation: a randomised trial (PubMed)

Effectiveness of amiodarone versus bepridil in achieving conversion to sinus rhythm in patients with persistent atrial fibrillation: a randomised trial Pharmacological conversion to sinus rhythm is generally difficult to achieve, particularly in long-lasting persistent atrial fibrillation (AF). The purpose of this study is to compare the effectiveness of two agents, amiodarone and bepridil, in achieving conversion to sinus rhythm in patients with persistent AF.Amiodarone (A) or bepridil (B (...) developed interstitial pneumonia, but steroid therapy cured the condition.Bepridil was superior to amiodarone in achieving sinus conversion and in maintaining sinus rhythm after cardioversion in patients with persistent AF. Even so, we must be watchful for potentially serious adverse complications when administering bepridil.

2012 EvidenceUpdates Controlled trial quality: uncertain

18. Amiodarone Significantly Decreases Atrial Fibrillation in Patients Undergoing Surgery for Lung Cancer (PubMed)

Amiodarone Significantly Decreases Atrial Fibrillation in Patients Undergoing Surgery for Lung Cancer Postoperative atrial fibrillation occurs in 5% to 65% of patients undergoing thoracic surgery. Although postoperative atrial fibrillation often is regarded as a temporary, benign, operation-related problem, it is associated with a twofold to threefold increase in risk of adverse events, including transient or permanent stroke, acute myocardial infarction, and death.A total of 254 consecutively (...) eligible enrolled patients undergoing surgery for lung cancer were included in this randomized, controlled, double-blinded trial. Patients received 300 mg of amiodarone or placebo intravenously over 20 minutes immediately after surgery and an oral dose of 600 mg of amiodarone or placebo twice daily during the first 5 postoperative days.The patients in the amiodarone prophylaxis group had a reduction in the risk of atrial fibrillation of 23% (12 to 31); number needed to treat was 4.4 (3.1 to 7.8

2012 EvidenceUpdates Controlled trial quality: predicted high

19. Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation

Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

20. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation (PubMed)

A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation This randomized double-blind study compared the efficacy and safety of intravenous vernakalant and amiodarone for the acute conversion of recent-onset atrial fibrillation (AF).Intravenous vernakalant has effectively converted recent-onset AF and was well tolerated in placebo-controlled studies.A total of 254 adult patients with AF (3 to 48 h duration) eligible (...) for cardioversion were enrolled in the study. Patients received either a 10-min infusion of vernakalant (3 mg/kg) followed by a 15-min observation period and a second 10-min infusion (2 mg/kg) if still in AF, plus a sham amiodarone infusion, or a 60-min infusion of amiodarone (5 mg/kg) followed by a maintenance infusion (50 mg) over an additional 60 min, plus a sham vernakalant infusion.Conversion from AF to sinus rhythm within the first 90 min (primary end point) was achieved in 60 of 116 (51.7%) vernakalant

Full Text available with Trip Pro

2011 EvidenceUpdates Controlled trial quality: predicted high